Clearmind Medicine Gets IRB Approval for AUD Trial
Ticker: CMND · Form: 6-K · Filed: Aug 5, 2025 · CIK: 1892500
Sentiment: bullish
Topics: clinical-trial, regulatory-approval, pharmaceuticals, healthcare
TL;DR
Clearmind (CMND) got the green light for its AUD drug trial at Hadassah. Big step forward.
AI Summary
Clearmind Medicine Inc. announced on August 5, 2025, that it has received Institutional Review Board (IRB) approval to commence a Phase 1/2a clinical trial for its alcohol use disorder (AUD) treatment at Hadassah Medical Center. This trial will evaluate the safety and efficacy of the treatment in patients with AUD.
Why It Matters
This IRB approval is a critical step for Clearmind Medicine, allowing them to advance their novel treatment for alcohol use disorder into human clinical trials, potentially offering a new therapeutic option for a widespread health issue.
Risk Assessment
Risk Level: medium — Clinical trial progress is inherently risky, with potential for delays, unexpected results, or regulatory hurdles.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- August 5, 2025 (date) — Announcement Date
- Hadassah Medical Center (company) — Clinical Trial Site
- 001-41557 (other) — SEC File Number
FAQ
What is the purpose of the Phase 1/2a clinical trial?
The trial aims to evaluate the safety and efficacy of Clearmind Medicine's treatment for alcohol use disorder (AUD) in patients.
Where will the clinical trial be conducted?
The clinical trial will be conducted at Hadassah Medical Center.
What is the specific condition being treated in the trial?
The trial is for alcohol use disorder (AUD).
What type of approval did Clearmind Medicine receive?
Clearmind Medicine received Institutional Review Board (IRB) approval.
What is the filing date of this Form 6-K?
This Form 6-K was filed on August 5, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on August 5, 2025 regarding Clearmind Medicine Inc. (CMND).